Sign In
Buy BSEM
$4.14
-0.0290 (-0.696%)
At Close: Jun 03, 2026
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
07:00am, Wednesday, 20'th Nov 2024
Additions of ProgenaMatrix®and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem's commercial product portfolio POMPANO BEACH, Fla., November 20, 2024 – PRISM MediaWire – Bio
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
07:00am, Wednesday, 20'th Nov 2024
POMPANO BEACH, Fla., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-deri
Long-Term, BioStem Technologies Still A Promising Growth Stock
09:08am, Friday, 15'th Nov 2024
BioStem Technologies has experienced significant price volatility, driven by positive news and uplisting plans, but recent profit-taking has caused a pullback. Q3 earnings report showed impressive gro
BioStem Technologies, Inc. (BSEM) Q3 2024 Earnings Call Transcript
06:42am, Friday, 15'th Nov 2024
BioStem Technologies, Inc. (OTCPK:BSEM) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executive Offi
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
07:30am, Tuesday, 12'th Nov 2024
POMPANO BEACH, FL, November 12, 2024 – PRISM MediaWire – BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufact
The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin marketing initiatives with Venture Medical POMPANO BEACH, Fla., October
POMPANO BEACH, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-deri
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
02:03pm, Monday, 28'th Oct 2024
Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., October 28, 2024 – PRISM MediaWire – BioStem Technologies Inc.
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
01:58pm, Monday, 28'th Oct 2024
POMPANO BEACH, Fla., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-deri
BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT
07:00am, Wednesday, 23'rd Oct 2024
Presentation to be webcast, with management participating in 1-on-1 meetings at the Luxe Sunset Boulevard Hotel in Los Angeles Pompano Beach, Florida--(Newsfile Corp. - October 23, 2024) - BioStem Tec
Retrospective Study demonstrates clinical efficacy and statistical support for tissue processed via BioREtain to care for treatment-resistant chronic wounds Study published in the peer-reviewed journa
Vendaje AC to launch across MAC regions nationwide through Venture Medical, the Company's exclusive sales and marketing partner for AmnioWrap2® POMPANO BEACH, Fla., Oct. 15, 2024 – PRISM MediaWire
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
07:00am, Wednesday, 02'nd Oct 2024
Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth The study will be conducted in 60 pat
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
07:00am, Wednesday, 02'nd Oct 2024
Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth The study will be conducted in 60 pat
Nasdaq listing aims to increase market visibility and global liquidity opportunities as BioStem advances its commercial and clinical initiatives amid record revenue growth Pompano Beach, FL, September
